In this article, we are going to take a look at where Akebia Therapeutics, Inc. (NASDAQ:AKBA) stands against other stocks to invest in for a stock market game. We all have heard the phrase ...

In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of ... antibodies for severe autoimmune/allergic diseases and cancer is expected to post quarterly loss of $0.76 per share in its upcoming ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $6.00. The company’s shares ...

The firm increased its portfolio allocation in AKBA by 41.87% over the last quarter. Geode Capital Management holds 4,795K shares representing 2.03% ownership of the company. In its prior filing ...

HC Wainwright restated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research report released on Friday,Benzinga reports. The brokerage currently has a $7.50 ...

AKEBIA THERAPEUTICS ($AKBA) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.10 per share, missing estimates of -$0.08 ...